Mitral regurgitation (MR) is the most common heart valve disease. In recent years, the rise of interventional therapy has expanded the indications of interventional treatment for patients with MR, but the epidemiological characteristics of MR (especially the number of patients with MR requiring treatment) in China are still unclear. In this paper, we analyzed and estimated the number of MR patients in China based on three epidemiological studies in Europe and America, and referring to the patients population surveys from Zhongshan Hospital Affiliated to Fudan University, the Second Affiliated Hospital Zhejiang University School of Medicine and Beijing Fuwai Hospital. Our analysis estimated that about 7.5 million patients with MR need intervention in China, including about 5.5 million patients with severe MR.
Citation： PAN Wenzhi, ZHOU Daxin, GE Junbo. Estimation of the number of patients with mitral regurgitation in China. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2021, 28(5): 495-498. doi: 10.7507/1007-4848.202012080 Copy